Antibody array strategy for human growth factor secretome profiling of GH-secreting adenomas
- 48 Downloads
To test if the antibody array strategy could be utilized to simultaneously detect the secretion of multiple growth factors by human pituitary GH-adenomas and to measure octreotide-induced alterations.
Specimens of human pituitary adenomas were cultured and incubated with or without octreotide for 24 h. Conditional media were analyzed by human growth factor antibody array and VEGF concentrations were measured by ELISA. Media were also analyzed for GH concentrations. p21 expression levels were examined by Western blot of the specimens lysates.
The antibody arrays successfully identified growth factors secreted by GH-adenomas in vitro. Octreotide treatment induced both elevations and reductions in growth factors secretion. GH response to octreotide was measured, and in this small-sized study resistant and sensitive GH-adenomas presented with no unique secretome pattern of each of the groups. Octreotide-induced VEGF alterations analyzed by the antibody array and by ELISA were not fully matched.
This study suggests that the broad proteomic strategy of antibody arrays may be utilized to study the growth factors secretion pattern of GH-adenomas and its regulation by somatostatin analogs or other compounds.
KeywordsGH-adenomas Growth factors Secretome VEGF
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Johnson LK, Baxter JD, Vlodavsky I, Gospodarowicz D (1980) Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response. Proc Natl Acad Sci USA 77(1):394–398Google Scholar
- 2.Schonbrunn A, Krasnoff M, Westendorf JM, Tashjian AH Jr (1980) Epidermal growth factor and thyrotropin-releasing hormone act similarly on a clonal pituitary cell strain. Modulation of hormone production and inhbition of cell proliferation. J Cell Biol 85(3):786–797Google Scholar
- 7.Atkin SL, Landolt AM, Jeffreys RV, Diver M, Radcliffe J, White MC (1993) Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation. J Clin Endocrinol Metabol 77(3):831–837Google Scholar
- 8.Baird A, Mormede P, Ying SY, Wehrenberg WB, Ueno N, Ling N, Guillemin R (1985) A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. Proc Natl Acad Sci USA 82(16):5545–5549Google Scholar
- 9.Liu HZ, Luo P, Chen SH, Shang JH (2013) Basic fibroblast growth factor upregulates expression of growth hormone gene through extracellular signal-regulated kinase 1/2 in GH4 cells. Bratislavske lekarske listy 114(7):376–379Google Scholar
- 10.Mallo F, Wilson E, Whorwood CB, Singh S, Sheppard MC (1995) Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells. Mol Cell Endocrinol 114(1–2):117–125Google Scholar
- 13.Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91–102Google Scholar
- 14.Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC (2013) Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 16(1):91–100. https://doi.org/10.1007/s11102-012-0380-1 Google Scholar
- 16.Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, Scoazec JY (2010) VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91(3):268–278. https://doi.org/10.1159/000289569 Google Scholar
- 18.Hayry P, Raisanen A, Ustinov J, Mennander A, Paavonen T (1993) Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J 7(11):1055–1060Google Scholar
- 21.Missale C, Fiorentini C, Finardi A, Spano P (1999) Growth factors in pituitary tumors. Pituitary 1(3–4):153–158Google Scholar
- 23.Renner U, Paez-Pereda M, Arzt E, Stalla GK (2004) Growth factors and cytokines: function and molecular regulation in pituitary adenomas. Front Hormone Res 32:96–109Google Scholar
- 24.Renner U, Pagotto U, Arzt E, Stalla GK (1996) Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol 135(5):515–532Google Scholar
- 26.Spada A, Lania A (2002) Growth factors and human pituitary adenomas. Mol Cell Endocrinol 197(1–2):63–68Google Scholar
- 27.Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86(6):2779–2786. https://doi.org/10.1210/jcem.86.6.7556 Google Scholar
- 30.Luque RM, Rodriguez-Pacheco F, Tena-Sempere M, Gracia-Navarro F, Malagon MM, Castano JP (2005) Differential contribution of nitric oxide and cGMP to the stimulatory effects of growth hormone-releasing hormone and low-concentration somatostatin on growth hormone release from somatotrophs. J Neuroendocrinol 17(9):577–582. https://doi.org/10.1111/j.1365-2826.2005.01345.x Google Scholar
- 31.Luque RM, Duran-Prado M, Garcia-Navarro S, Gracia-Navarro F, Kineman RD, Malagon MM, Castano JP (2006) Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion. Endocrinology 147(6):2902–2908. https://doi.org/10.1210/en.2005-1559 Google Scholar
- 32.Cordoba-Chacon J, Gahete MD, Culler MD, Castano JP, Kineman RD, Luque RM (2012) Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP. J Neuroendocrinol 24(3):453–463. https://doi.org/10.1111/j.1365-2826.2011.02261.x Google Scholar
- 34.Uretsky AD, Weiss BL, Yunker WK, Chang JP (2003) Nitric oxide produced by a novel nitric oxide synthase isoform is necessary for gonadotropin-releasing hormone-induced growth hormone secretion via a cGMP-dependent mechanism. J Neuroendocrinol 15(7):667–676Google Scholar